COMMUNIQUÉS West-GlobeNewswire

Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights
26/10/2026
Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in November 2026 IND filing for the Enhanced Brain Delivery™ (EBD ® ) [...]
Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026
26/10/2026
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on November 10, 2026 NASHVILLE, Tenn., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease [...]
Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting
26/10/2026
Tegoprubart-treated patients demonstrated a mean improvement on the total MTSOSD-59R symptom occurrence scale at 12 months while tacrolimus-treated patients experienced a mean worsening of symptom occurrence [...]
BPGbio Presents Phase 2 Glioblastoma Data Update at ESMO Congress 2026, Highlighting Median Overall Survival of 19.9 Months in MGMT-Unmethylated Patients
26/10/2026
Median overall survival of 19.9 months in patients with MGMT-unmethylated glioblastoma compares favorably with historical outcomes BPM31510 demonstrated a well-tolerated safety profile in combination with standard-of- [...]
Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis
26/10/2026
61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group, highly similar to EVERLAST-A Continued favorable safety and tolerability profile consistent with the IL-23p19 class ORKA-001 on track to advance [...]
Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine
26/10/2026
Partnership combines Pluri’s proprietary cell technology and clinical-development experience with ZEO’s biologics manufacturing expertise, established physician network, and sales, marketing, and educational [...]
Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026
26/10/2026
Active LN patients in the Phase 1 study treated with FT819 and the less-intensive conditioning (bendamustine) regimen selected for the RECLAIM-LN study achieved 100% renal response at Month 6, with approximately 50% [...]
Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026
26/10/2026
Primary safety endpoint achieved; exploratory findings highlight encouraging survival outcomes in heavily pretreated patients One second-line patient achieved progression-free survival of 16.39 months and overall [...]
Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
26/10/2026
Media Release COPENHAGEN, Denmark; October 26, 2026 Median overall survival (OS) outcomes and encouraging anti-tumor activity observed with petosemtamab plus pembrolizumab in first-line (1L) recurrent or metastatic PD- [...]
InnoCare Reports 2026 Q3 Results, Sustained Profitability and Accelerating Globalization
26/10/2026
BEIJING, Oct. 26, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced its third quarter 2026 results and [...]
Newsweek Places KFSH in Top 4% of World's Smart Hospitals for Digital Maturity and AI
26/10/2026
RIYADH, Saudi Arabia, Oct. 26, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH) is one of only 15 hospitals worldwide to receive both the maximum five-ribbon digital maturity rating [...]
Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress
26/10/2026
TLR7/8 dual-agonist EIK1001 plus pembrolizumab and chemotherapy in first-line, stage 4 non-small cell lung cancer (NSCLC) demonstrates durable effect in combination with standard-of-care, and a tolerability profile [...]
BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer
26/10/2026
MAINZ, Germany and SHANGHAI, China, October 26, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and DualityBiologics (Suzhou) Co., Ltd. (“DualityBio”, HKEX: 9606.HK) announced today that the DYNASTY-Breast02 global Phase [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
26/10/2026
COPENHAGEN, Denmark, October 26, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an amount [...]
HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026
26/10/2026
— ORPATHYS ® plus TAGRISSO ® reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting — — Robust PFS gains alongside [...]
NTG Nordic Transport Group A/S - Upgrade of guidance for the full year 2026
26/10/2026
Company announcement no. 41 – 26 26 October 2026 NTG Nordic Transport Group A/S - Upgrade of guidance for the full year 2026 Based on preliminary financial results for the third quarter of 2026, NTG expects adjusted [...]
Phathom Pharmaceuticals Provides Update on FDA Litigation
26/10/2026
FLORHAM PARK, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) [...]
TME Pharma extends financial visibility by lengthening debt maturity to June 2028
26/10/2026
TME Pharma extends financial visibility by lengthening debt maturity to June 2028 Financial visibility extended to second quarter of 2028 All existing debt holders, including the CEO and two members of the Supervisory [...]
TME Pharma améliore sa visibilité financière en prolongeant l'échéance de sa dette jusqu'en juin 2028
26/10/2026
TME Pharma améliore sa visibilité financière en prolongeant l'échéance de sa dette jusqu'en juin 2028 Visibilité financière prolongée jusqu'au deuxième trimestre 2028 Tous les détenteurs de dette existants, y compris le [...]

Pages